Tag: aplisol market growth

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Apidra Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The historical expansion witnessed can be traced to the increasing prevalence of diabetes, the proven efficacy of rapid-acting insulin, heightened physician familiarity with insulin analogs, the establishment of hospital diabetes protocols, and the greater adoption of patient self-management.

Anticipated growth over the forecast period is driven by factors such as an increasing incidence of type 2 diabetes, a growing elderly population, enhanced understanding of diabetes, advancements in insulin delivery technology, and the expansion of healthcare in developing economies. Key developments observed during this period encompass a heightened demand for rapid-acting insulins, the proliferation of intensive glycemic management, the provision of both inpatient and outpatient diabetes care, the increasing adoption of combination insulin therapy, and a significant emphasis on regulating post-meal blood sugar levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19973&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Apidra Market?

The growing occurrence of diabetes is projected to propel the expansion of the apidra market in the future. Diabetes is a persistent medical ailment marked by the body’s impaired ability to properly manage blood sugar (glucose) concentrations. The escalating frequency of diabetes, driven by elements like aging demographics, inactive routines, and increasing obesity rates, has significantly boosted the demand for rapid-acting insulin therapies such as apidra. Apidra (insulin glulisine) assists diabetes patients by quickly stabilizing blood sugar levels post-meals, mirroring the body’s inherent insulin response, and offering adaptability in managing their condition to lower the danger of hyperglycemia and enhance overall glycemic control. For instance, in May 2024, as per the British Diabetic Association (Diabetes UK), a charitable organization based in the UK, approximately 4.4 million individuals in the UK are living with diabetes, with type 1 diabetes accounting for about 8% of incidents and type 2 diabetes making up nearly 90%. Consequently, the rising prevalence of diabetes is a key factor driving the growth of the apidra market.

Apidra Market Driver: Rising Healthcare Expenditure Drive Growth Of The Market

An increase in healthcare spending is anticipated to foster the growth of the apidra market moving forward. Healthcare expenditure signifies the cumulative financial outlay on health-related services, encompassing medical care, hospital services, pharmaceutical products, and public health initiatives, by governmental bodies, private enterprises, and individuals. The escalating need for healthcare expenditure stems from the increasing incidence of chronic illnesses, which necessitate prolonged and expensive treatments. Elevated healthcare spending supports the adoption of Apidra by broadening access to rapid-acting insulin therapies, thereby making diabetes management more effective for patients. It allows healthcare systems to invest in advanced treatment options, promoting better glycemic control and improving patient health outcomes overall. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, marking an increase of 0.9% growth compared to 2022. Hence, the escalating healthcare expenditure is a significant factor driving the growth of the apidra market.

What Major Segment Divisions Exist Within The Apidra Market?

The apidra market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Provider

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Companies Are Leading Innovation In The Apidra Market?

Major companies operating in the apidra market are Sanofi S.A.

Read the full apidra market report here:

https://www.thebusinessresearchcompany.com/report/apidra-global-market-report

What Are The Leading Geographic Regions In The Apidra Market?

North America was the largest region in the apidra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apidra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Apidra Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19973&type=smp

Browse Through More Reports Similar to the Global Apidra Market 2026, By The Business Research Company

Apixaban Market Report 2026

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Apiculture Market Report 2026

https://www.thebusinessresearchcompany.com/report/apiculture-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Apidra Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The historical expansion witnessed can be traced to the increasing prevalence of diabetes, the proven efficacy of rapid-acting insulin, heightened physician familiarity with insulin analogs, the establishment of hospital diabetes protocols, and the greater adoption of patient self-management.

Anticipated growth over the forecast period is driven by factors such as an increasing incidence of type 2 diabetes, a growing elderly population, enhanced understanding of diabetes, advancements in insulin delivery technology, and the expansion of healthcare in developing economies. Key developments observed during this period encompass a heightened demand for rapid-acting insulins, the proliferation of intensive glycemic management, the provision of both inpatient and outpatient diabetes care, the increasing adoption of combination insulin therapy, and a significant emphasis on regulating post-meal blood sugar levels.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19973&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Apidra Market?

The growing occurrence of diabetes is projected to propel the expansion of the apidra market in the future. Diabetes is a persistent medical ailment marked by the body’s impaired ability to properly manage blood sugar (glucose) concentrations. The escalating frequency of diabetes, driven by elements like aging demographics, inactive routines, and increasing obesity rates, has significantly boosted the demand for rapid-acting insulin therapies such as apidra. Apidra (insulin glulisine) assists diabetes patients by quickly stabilizing blood sugar levels post-meals, mirroring the body’s inherent insulin response, and offering adaptability in managing their condition to lower the danger of hyperglycemia and enhance overall glycemic control. For instance, in May 2024, as per the British Diabetic Association (Diabetes UK), a charitable organization based in the UK, approximately 4.4 million individuals in the UK are living with diabetes, with type 1 diabetes accounting for about 8% of incidents and type 2 diabetes making up nearly 90%. Consequently, the rising prevalence of diabetes is a key factor driving the growth of the apidra market.

Apidra Market Driver: Rising Healthcare Expenditure Drive Growth Of The Market

An increase in healthcare spending is anticipated to foster the growth of the apidra market moving forward. Healthcare expenditure signifies the cumulative financial outlay on health-related services, encompassing medical care, hospital services, pharmaceutical products, and public health initiatives, by governmental bodies, private enterprises, and individuals. The escalating need for healthcare expenditure stems from the increasing incidence of chronic illnesses, which necessitate prolonged and expensive treatments. Elevated healthcare spending supports the adoption of Apidra by broadening access to rapid-acting insulin therapies, thereby making diabetes management more effective for patients. It allows healthcare systems to invest in advanced treatment options, promoting better glycemic control and improving patient health outcomes overall. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure experienced a 5.6% rise in nominal terms in 2023, marking an increase of 0.9% growth compared to 2022. Hence, the escalating healthcare expenditure is a significant factor driving the growth of the apidra market.

What Major Segment Divisions Exist Within The Apidra Market?

The apidra market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Provider

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Companies Are Leading Innovation In The Apidra Market?

Major companies operating in the apidra market are Sanofi S.A.

Read the full apidra market report here:

https://www.thebusinessresearchcompany.com/report/apidra-global-market-report

What Are The Leading Geographic Regions In The Apidra Market?

North America was the largest region in the apidra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apidra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Apidra Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19973&type=smp

Browse Through More Reports Similar to the Global Apidra Market 2026, By The Business Research Company

Apixaban Market Report 2026

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Apiculture Market Report 2026

https://www.thebusinessresearchcompany.com/report/apiculture-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the apidra market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Apidra Market between 2026 and 2030?

Historical expansion was driven by a rise in diabetes cases, the efficacy of rapid-acting insulin, medical professionals’ acquaintance with insulin analogs, established diabetes guidelines in hospitals, and increased patient engagement in managing their own condition.

Market expansion during the forecast period is fueled by an increasing prevalence of type 2 diabetes, a growing elderly population, enhanced understanding of diabetes, innovations in insulin delivery systems, and the development of healthcare infrastructure in nascent markets. Significant trends expected within the same period encompass a heightened requirement for rapid-acting insulins, the advancement of intensive glycemic management, the provision of diabetes care in both hospital and home environments, the wider acceptance of combination insulin therapy, and a specific focus on controlling post-meal glucose levels.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19973&type=smp

Which Drivers Are Expected To Impact The Apidra Market During The Forecast Period?

The growing incidence of diabetes is projected to fuel the expansion of the apidra market moving forward. Diabetes is a long-term medical condition marked by the body’s inability to adequately manage blood sugar (glucose) levels. The increasing occurrence of diabetes, influenced by factors such as an aging populace, inactive lifestyles, and escalating obesity rates, has heightened the need for quick-acting insulin therapies like apidra. Apidra (insulin glulisine) assists diabetes patients by quickly regulating blood sugar concentrations after meals, mirroring the body’s natural insulin release, and offering flexibility in managing their condition to lower the risk of hyperglycemia and enhance overall glycemic control. For instance, in May 2024, figures from the British Diabetic Association (Diabetes UK), a UK-based charitable body, indicated that approximately 4.4 million people in the UK are living with diabetes, with type 1 diabetes accounting for about 8% of cases and type 2 diabetes making up nearly 90%. Consequently, the increasing prevalence of diabetes is fostering the growth of the apidra market. The escalating healthcare expenditure is anticipated to drive the apidra market’s growth in the coming period. Healthcare expenditure denotes the total financial outlay on healthcare provisions, encompassing medical treatments, hospital care, medications, and public health initiatives, by governmental bodies, businesses, and individuals. The heightened demand for healthcare spending stems from the rising prevalence of chronic conditions, which necessitate prolonged and expensive treatments. Elevated healthcare expenditure facilitates the adoption of Apidra by broadening access to rapid-acting insulin therapies, thereby making diabetes management more effective for patients. It allows healthcare systems to invest in advanced treatment options, promoting better glycemic regulation and improving overall patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% increase in nominal terms during 2023, reflecting a 0.9% growth compared to 2022. Hence, the rising healthcare expenditure is propelling the expansion of the apidra market.

Which Segments Are Driving Activity In The Apidra Market?

The apidra market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Provider

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Major Industry Participants Are Leading The Apidra Market Growth?

Major companies operating in the apidra market are Sanofi S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/apidra-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Apidra Market?

North America was the largest region in the apidra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apidra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Apidra Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19973&type=smp

Browse Through More Reports Similar to the Global Apidra Market 2026, By The Business Research Company

Apixaban Market Report 2026

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Apiculture Market Report 2026

https://www.thebusinessresearchcompany.com/report/apiculture-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the apidra market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Apidra Market between 2026 and 2030?

Historical expansion was driven by a rise in diabetes cases, the efficacy of rapid-acting insulin, medical professionals’ acquaintance with insulin analogs, established diabetes guidelines in hospitals, and increased patient engagement in managing their own condition.

Market expansion during the forecast period is fueled by an increasing prevalence of type 2 diabetes, a growing elderly population, enhanced understanding of diabetes, innovations in insulin delivery systems, and the development of healthcare infrastructure in nascent markets. Significant trends expected within the same period encompass a heightened requirement for rapid-acting insulins, the advancement of intensive glycemic management, the provision of diabetes care in both hospital and home environments, the wider acceptance of combination insulin therapy, and a specific focus on controlling post-meal glucose levels.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19973&type=smp

Which Drivers Are Expected To Impact The Apidra Market During The Forecast Period?

The growing incidence of diabetes is projected to fuel the expansion of the apidra market moving forward. Diabetes is a long-term medical condition marked by the body’s inability to adequately manage blood sugar (glucose) levels. The increasing occurrence of diabetes, influenced by factors such as an aging populace, inactive lifestyles, and escalating obesity rates, has heightened the need for quick-acting insulin therapies like apidra. Apidra (insulin glulisine) assists diabetes patients by quickly regulating blood sugar concentrations after meals, mirroring the body’s natural insulin release, and offering flexibility in managing their condition to lower the risk of hyperglycemia and enhance overall glycemic control. For instance, in May 2024, figures from the British Diabetic Association (Diabetes UK), a UK-based charitable body, indicated that approximately 4.4 million people in the UK are living with diabetes, with type 1 diabetes accounting for about 8% of cases and type 2 diabetes making up nearly 90%. Consequently, the increasing prevalence of diabetes is fostering the growth of the apidra market. The escalating healthcare expenditure is anticipated to drive the apidra market’s growth in the coming period. Healthcare expenditure denotes the total financial outlay on healthcare provisions, encompassing medical treatments, hospital care, medications, and public health initiatives, by governmental bodies, businesses, and individuals. The heightened demand for healthcare spending stems from the rising prevalence of chronic conditions, which necessitate prolonged and expensive treatments. Elevated healthcare expenditure facilitates the adoption of Apidra by broadening access to rapid-acting insulin therapies, thereby making diabetes management more effective for patients. It allows healthcare systems to invest in advanced treatment options, promoting better glycemic regulation and improving overall patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% increase in nominal terms during 2023, reflecting a 0.9% growth compared to 2022. Hence, the rising healthcare expenditure is propelling the expansion of the apidra market.

Which Segments Are Driving Activity In The Apidra Market?

The apidra market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Provider

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Major Industry Participants Are Leading The Apidra Market Growth?

Major companies operating in the apidra market are Sanofi S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/apidra-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Apidra Market?

North America was the largest region in the apidra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apidra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Apidra Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19973&type=smp

Browse Through More Reports Similar to the Global Apidra Market 2026, By The Business Research Company

Apixaban Market Report 2026

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Apiculture Market Report 2026

https://www.thebusinessresearchcompany.com/report/apiculture-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the apidra market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Apidra Market between 2026 and 2030?

Historical expansion was driven by a rise in diabetes cases, the efficacy of rapid-acting insulin, medical professionals’ acquaintance with insulin analogs, established diabetes guidelines in hospitals, and increased patient engagement in managing their own condition.

Market expansion during the forecast period is fueled by an increasing prevalence of type 2 diabetes, a growing elderly population, enhanced understanding of diabetes, innovations in insulin delivery systems, and the development of healthcare infrastructure in nascent markets. Significant trends expected within the same period encompass a heightened requirement for rapid-acting insulins, the advancement of intensive glycemic management, the provision of diabetes care in both hospital and home environments, the wider acceptance of combination insulin therapy, and a specific focus on controlling post-meal glucose levels.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19973&type=smp

Which Drivers Are Expected To Impact The Apidra Market During The Forecast Period?

The growing incidence of diabetes is projected to fuel the expansion of the apidra market moving forward. Diabetes is a long-term medical condition marked by the body’s inability to adequately manage blood sugar (glucose) levels. The increasing occurrence of diabetes, influenced by factors such as an aging populace, inactive lifestyles, and escalating obesity rates, has heightened the need for quick-acting insulin therapies like apidra. Apidra (insulin glulisine) assists diabetes patients by quickly regulating blood sugar concentrations after meals, mirroring the body’s natural insulin release, and offering flexibility in managing their condition to lower the risk of hyperglycemia and enhance overall glycemic control. For instance, in May 2024, figures from the British Diabetic Association (Diabetes UK), a UK-based charitable body, indicated that approximately 4.4 million people in the UK are living with diabetes, with type 1 diabetes accounting for about 8% of cases and type 2 diabetes making up nearly 90%. Consequently, the increasing prevalence of diabetes is fostering the growth of the apidra market. The escalating healthcare expenditure is anticipated to drive the apidra market’s growth in the coming period. Healthcare expenditure denotes the total financial outlay on healthcare provisions, encompassing medical treatments, hospital care, medications, and public health initiatives, by governmental bodies, businesses, and individuals. The heightened demand for healthcare spending stems from the rising prevalence of chronic conditions, which necessitate prolonged and expensive treatments. Elevated healthcare expenditure facilitates the adoption of Apidra by broadening access to rapid-acting insulin therapies, thereby making diabetes management more effective for patients. It allows healthcare systems to invest in advanced treatment options, promoting better glycemic regulation and improving overall patient outcomes. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that total healthcare expenditure experienced a 5.6% increase in nominal terms during 2023, reflecting a 0.9% growth compared to 2022. Hence, the rising healthcare expenditure is propelling the expansion of the apidra market.

Which Segments Are Driving Activity In The Apidra Market?

The apidra market covered in this report is segmented –

1) By Indication: Type 1 Diabetes, Type 2 Diabetes

2) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Provider

3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

Which Major Industry Participants Are Leading The Apidra Market Growth?

Major companies operating in the apidra market are Sanofi S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/apidra-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Apidra Market?

North America was the largest region in the apidra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apidra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Apidra Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19973&type=smp

Browse Through More Reports Similar to the Global Apidra Market 2026, By The Business Research Company

Apixaban Market Report 2026

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Apiculture Market Report 2026

https://www.thebusinessresearchcompany.com/report/apiculture-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model